 |
| A boy receives an HIV test at a PEPFAR-funded clinic in South Africa |
The President's Emergency Plan for AIDS Relief (PEPFAR), a successful bipartisan initiative that has saved 25 million lives globally from HIV/AIDS over the past two decades, is now at risk due to a political dispute. Congress and the White House have consistently reauthorized the program every five years, regardless of the party in power, and it has been praised for sparing entire countries from the devastation of the AIDS epidemic.
However, as the program faces renewal this fall, domestic pro-life organizations, including Susan B. Anthony Pro-Life America and The Heritage Foundation's action arm, Heritage Action, have voiced opposition, warning that supporting PEPFAR's reauthorization could negatively affect a lawmaker's pro-life scorecard. The Family Research Council has also announced plans to score the vote.
The pro-life groups argue that the Biden administration is attempting to use PEPFAR funds to promote and provide abortions. Pro-life advocates involved in combating HIV/AIDS abroad have refuted these claims, asserting that funding or promoting abortion through PEPFAR would be illegal under US law. Moreover, abortion is either illegal or highly restricted in most PEPFAR-funded countries, primarily in Africa.
The dispute has left PEPFAR's future in jeopardy, with negotiations ongoing but prospects for a smooth reauthorization appearing grim. Pro-life critics suggest extending funding for only one year, but longstanding supporters of PEPFAR warn that this approach would subject the program to annual appropriations, making it vulnerable to budget cuts and uncertainties.
PEPFAR's predictable five-year reauthorization cycle has been instrumental in maintaining controls on fund allocations, conscience provisions, and auditing requirements, all of which prevent the program from funding abortions. Advocates argue that extending funding for just one year would expose the program to unnecessary political influence and hinder its effectiveness in combating the HIV/AIDS crisis.
Launched by President George W. Bush in 2003, PEPFAR's primary goal is to provide antiretroviral (ARV) drugs to individuals with HIV/AIDS and prevent further transmission of the disease. The program has significantly increased life expectancy in Africa, where 20 million people, mostly in African countries, currently receive treatment through PEPFAR.
PEPFAR has historically received support from Catholic and Protestant faith-based organizations, including those in Africa. However, debates over terminology such as "family planning" and "reproductive health" have always been contentious issues within the program. The Biden administration's recent addition of a footnote to clarify "reproductive health" under PEPFAR has failed to satisfy pro-life groups' concerns.
Republican Rep. Chris Smith has been a prominent figure opposing PEPFAR's five-year reauthorization on pro-life grounds, despite previously supporting the program. He emphasizes the need for the Mexico City Policy, which prohibits US-funded groups from supporting or advocating for abortions overseas. While the policy was not in place for most of PEPFAR's existence, other US laws, such as the Helms and Siljander Amendments, already prohibit funding or advocacy of abortion abroad using US dollars.
The concerns raised by pro-life groups stem from PEPFAR's work with contractors, some of whom may use non-PEPFAR funds to support abortion-related services. However, proponents of the program argue that measures are in place to ensure that PEPFAR funding is not misused for abortions. They stress that PEPFAR's impact in combating HIV/AIDS has been immense and warn that any disruption to the program could be detrimental to the progress made over the years.
As PEPFAR's authorization is set to expire on September 30, there is still a chance for both sides to find common ground and resolve the dispute through dialogue and collaboration. The hope is that the pro-life community and PEPFAR advocates can come together to continue the life-saving work of the program and make further strides toward controlling the HIV/AIDS epidemic.
